Fesoterodine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fesoterodine" in English language version.

refsWebsite

Global rank English rank

4web.archive.org

1^st place

1^st place

2^nd place

2^nd place

1,712^th place

1,063^rd place

1medicalnewstoday.com

3,011^th place

2,709^th place

68^th place

117^th place

399^th place

333^rd place

low place

8,167^th place

4^th place

4^th place

1semanticscholar.org

11^th place

8^th place

5^th place

5^th place

canada.ca

"Product monograph brand safety updates". Health Canada. 6 June 2024. Retrieved 8 June 2024.

doi.org

Vella M, Cardozo L (September 2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–8. doi:10.1517/14740338.2011.591377. PMID 21639817. S2CID 9653506.
"Sato N, Fuji K, Ogawa Y (2017). "Transactions of The Showa University Society: The 335th Meeting". The Showa University Journal of Medical Sciences. 29 (2): 201–217. doi:10.15369/sujms.29.201. ISSN 2185-0968.

drugs.com

"Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Archived from the original on 2018-09-20. Retrieved 2008-11-06.

europa.eu

emea.europa.eu

"Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. Archived from the original on 2008-04-01.

hc-sc.gc.ca

"Notice of Decision for TOVIAZ". Archived from the original on 2012-04-23. Retrieved 2012-04-20.

medicalnewstoday.com

"Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Archived from the original on 16 May 2011. Retrieved 2 November 2007.

nih.gov

pubmed.ncbi.nlm.nih.gov

Vella M, Cardozo L (September 2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–8. doi:10.1517/14740338.2011.591377. PMID 21639817. S2CID 9653506.

semanticscholar.org

api.semanticscholar.org

Vella M, Cardozo L (September 2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–8. doi:10.1517/14740338.2011.591377. PMID 21639817. S2CID 9653506.

web.archive.org

"Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Archived from the original on 16 May 2011. Retrieved 2 November 2007.
"Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. Archived from the original on 2008-04-01.
"Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Archived from the original on 2018-09-20. Retrieved 2008-11-06.
"Notice of Decision for TOVIAZ". Archived from the original on 2012-04-23. Retrieved 2012-04-20.

worldcat.org

search.worldcat.org

"Sato N, Fuji K, Ogawa Y (2017). "Transactions of The Showa University Society: The 335th Meeting". The Showa University Journal of Medical Sciences. 29 (2): 201–217. doi:10.15369/sujms.29.201. ISSN 2185-0968.